Lupus Nephritis (LN) is a chronic kidney disease that occurs in up to half of patients with Systemic Lupus Erythematosus (SLE, lupus).

Currently, there is no consistent treatment for LN, and patients often rely on broad immunosuppressive courses. In refractory cases, dialysis and/or transplantation become necessary.

Ontegimod is expected to effectively prevent inflammatory kidney damage without the toxicity and side effects associated with strong immunosuppressants, owing to the autoimmune nature of the disease.